

## ANSWERING REVIEWERS

November 19, 2013



Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: PFO-WJC\_5b.docx).

**Title:** Percutaneous closure of patent foramen ovale: “Closed” door after the last randomized trials?

**Author:** Joel Hernandez, Raul Moreno

**Name of Journal:** *World Journal of Cardiology*

**ESPS Manuscript NO:** 6052

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) Format has been updated.

(2) None.

(3) Opinion on PFO closure in current practice in patients where oral anticoagulation is contraindicated is given.

(4) The conclusion is expressed in a softer manner. The available pro Amplatzer data is given. ESC Guidelines for the management of grown-up congenital heart disease do not specifically comment on the management of patent foramen ovale. Guidelines for the prevention of stroke and Guidelines for the management of atrial fibrillation are cited. “Amplatzer” typos are corrected.

3 References and typesetting were corrected.

Thank you again for publishing our manuscript in the *World Journal of Cardiology*.

Sincerely yours,

Raul Moreno, MD, PhD, FESC

Director of Interventional Cardiology

University Hospital La Paz

Paseo La Castellana, 261

28045 Madrid, Spain

E-mail: [raulmorenog@hotmail.com](mailto:raulmorenog@hotmail.com)

Telephone: (34)687483054